(Z)-1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(p-tolylamino)but-2-en-1-one | 1384485-99-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (Z)-1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(p-tolylamino)but-2-en-1-one
• CAS: 1384485-99-7
• 化学式: C₂₁H₂₁N₃O₂
• 分子量: 347.417
• InChiKey: IPQBKSRHGTZBAQ-SQFISAMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.39
• 重原子数：
  26.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  67.15
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (Z)-1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(p-tolylamino)but-2-en-1-one 、 三光气 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以85%的产率得到(6E)-4-methyl-6-(3-methyl-5-oxo-1-phenylpyrazol-4-ylidene)-3-(4-methylphenyl)-1,3-oxazin-2-one
  参考文献：
  名称：

  Synthesis and in silico biological activity evaluation of new N-substituted pyrazolo-oxazin-2-one systems

  摘要：

  Cyclisation of pyrazolo-beta-enaminones 3 readily obtained from 4-aceto acetyl pyrazol 2 with triphosgene led to the formation of N-substituted pyrazolo-1,3-oxazin-2-ones 4 in good yields. Estimation of pharmacotherapeutic potential, possible molecule mechanisms of action, toxic/side effects and interaction with drug-metabolizing enzymes were made for synthesised compounds on the basis of prediction of activity spectra for substances (PASS) prediction results and their analysis by PharmaExpert software. COX inhibition predicted by PASS was confirmed by experimental evaluation. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.12.033
• 作为产物：
  描述：

  1-(5-methyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)butane-1,3-dione 、 乙烷,三氯氟- 生成 (Z)-1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(p-tolylamino)but-2-en-1-one
  参考文献：
  名称：

  Synthesis and in silico biological activity evaluation of new N-substituted pyrazolo-oxazin-2-one systems

  摘要：

  Cyclisation of pyrazolo-beta-enaminones 3 readily obtained from 4-aceto acetyl pyrazol 2 with triphosgene led to the formation of N-substituted pyrazolo-1,3-oxazin-2-ones 4 in good yields. Estimation of pharmacotherapeutic potential, possible molecule mechanisms of action, toxic/side effects and interaction with drug-metabolizing enzymes were made for synthesised compounds on the basis of prediction of activity spectra for substances (PASS) prediction results and their analysis by PharmaExpert software. COX inhibition predicted by PASS was confirmed by experimental evaluation. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.12.033